X
<

Pfizer’s 2017 Performance in Review

PART:
1 2 3 4 5 6 7 8 9 10 11 12
Part 9
Pfizer’s 2017 Performance in Review PART 9 OF 12

Behind Pfizer’s Sterile Injection Pharmaceutical Performance in 2017

Medrol and Sulperazon revenue trends

In fiscal 2017, Pfizer’s (PFE) Medrol generated revenues of $483 million, which was ~7% higher on a YoY (year-over-year) basis. In 2017, in the US and in international markets, Medrol reported revenues of $317 million and $167 million, respectively, which was ~11% and ~1% higher on a YoY basis.

Medrol (methylprednisolone) is used to treat arthritis, blood disorders, allergic conditions, and different immune disorders. In 4Q17, Medrol reported revenues of $131 million, which represents a ~10% YoY rise and a 20% quarter-over-quarter rise.

Behind Pfizer’s Sterile Injection Pharmaceutical Performance in 2017

Interested in PFE? Don't miss the next report.

Receive e-mail alerts for new research on PFE

Success! You are now receiving e-mail alerts for new research. A temporary password for your new Market Realist account has been sent to your e-mail address.

Success! has been added to your Ticker Alerts.

Success! has been added to your Ticker Alerts. Subscriptions can be managed in your user profile.

In fiscal 2017, Sulperazon reported revenues of $471 million, which represents a ~19% rise on a YoY basis. In 4Q17, Sulperazon reported revenues of $126 million, which was ~36% higher YoY and ~11% higher quarter-over-quarter. Sulperazon’s market competitors include Merck’s (MRK) Primaxin.

Fragmin revenue trends

In 2017, Pfizer’s Fragmin reported revenues of $306 million, which was ~4% lower YoY. In 2017, in the US and in international markets, Fragmin generated revenues of $20 million and $286 million, respectively, compared with $30 million and $288 million in 2016.

Fragmin is an anticoagulant that prevents blood clots. Fragmin’s competitor drugs include Sanofi’s (SNY) Lovenox and Bristol-Myers Squibb’s (BMY) Coumadin. In 4Q17, Fragmin reported revenues of $85 million, which was ~8% higher YoY and 8% higher on a quarter-over-quarter basis.

Tygacil revenue trends

In 2017, Tygacil reported revenues of $260 million, which represents a ~5% YoY decline. In 2017, in the US and in international markets, Tygacil reported revenues of $45 million and $215 million, respectively, compared with $80 million and $193 million in 2016.

In 4Q17, Tygacil reported revenues of $69 million, which was ~4% lower on a YoY basis. In 4Q17, in the US and in international markets, Tygacil reported revenues of $6 million and 16 million, respectively, which reflected a ~61% decline on a YoY basis but a 13% rise quarter-over-quarter.

Tygacil (tigecycline) is used to treat skin infections, intra-abdominal infections, and community-acquired bacterial pneumonia.

Precedex revenue trends

In 2017, Precedex generated revenues of $243 million, which with ~8% lower YoY. In 2017, in the US and in international markets, Precedex reported revenues of $140 million and $104 million, respectively, compared with $162 million and $101 million in 2016.

In 4Q17, Precedex reported revenues of $61 million, which was ~5% lower YoY. In 4Q17, in the US and in international markets, Precedex reported revenues of $37 million and $24 million, respectively. In 4Q17, in international markets, Precedex witnessed a 13% fall on a YoY basis. In the US, Precedex’s YoY revenues remained flat.

In the next part of this series, we’ll discuss the performance of Pfizer’s Legacy Established Products segment in 4Q17 and 2017.

X

Please select a profession that best describes you: